SundrugSUNDRUG CO.,LTD.9989東証プライム小売業FY ending Mar 2026, consolidated, J-GAAP

Sundrug FY ending Mar 2026 results

About 57% of Sundrug's sales come from Drug store, with Discount store making up much of the rest.

Out of every ¥100 of sales, about ¥6 is left as operating profit.

Revenue changed +5.1% from the prior year, operating profit +5.2%.

Revenue and profit pattern

Revenue and profit upSimilar growth

Revenue +5.1% · profit +5.2%, calculated from disclosed figures.

Operating leverage: 1.03× (profit growth ÷ revenue growth)

What changed from last year

FY ending Mar 2025 → FY ending Mar 2026

Revenue: +5.1%¥801.8B → ¥842.5B
Gross profit: +5.9%¥204.1B → ¥216.2B
Operating income: +5.2%¥44.5B → ¥46.8B
Net income attributable to owners: +2.1%¥30.8B → ¥31.4B
Operating cash flow: +5.2%¥41.2B → ¥43.3B
Free cash flow: +76.3%¥6.9B → ¥12.2B

Results at a glance

Revenue for the FY ending Mar 2026 was ¥842.5B, up +5.1% from ¥801.8B.
Gross profit grew faster at +5.9%, but higher SG&A kept operating income growth to +5.2%, at ¥46.8B.
Net income rose only +2.1% to ¥31.4B.
Free cash flow climbed from ¥6.9B to ¥12.2B.

What drove the change

In drugstores, prescriptions and online sales stayed strong, stockpiled government rice sold well, and remodeled stores helped. Cold medicine and other seasonal items fell after a strong prior-year comparison.
In discount stores, food sales held up as market prices rose, while a warm winter hurt seasonal appliance sales.
Better purchasing terms lifted gross margin in both businesses. SG&A rose partly because of a temporary jump in depreciation from heavy investment.

Things to watch

Rivals and other retail formats keep opening stores and consolidating, which could cut customer traffic and spending per visit.
Dispensing fees and drug prices are set by the government, so revisions can hit earnings.
Hiring pharmacists and registered sellers is highly competitive; shortfalls could slow store openings and push up labor costs.

Annual Securities Report, 63rd fiscal period (Apr 2025 – Mar 2026) / 経営者による財政状態、経営成績及びキャッシュ・フローの状況の分析 · Annual Securities Report, 63rd fiscal period (Apr 2025 – Mar 2026) / 事業等のリスク

Where the money goes

FY ending Mar 2025 → FY ending Mar 2026

Where ¥100 of sales goes

For every ¥100 Sundrug sells, how much goes where, and how much is kept.

FY ending Mar 2026

Cost of sales: ¥74
SG&A: ¥20
Operating profit: ¥6
Net profit kept: ¥4

Annual margin trends

Gross margin25.7%

Operating margin5.6%

Net margin3.7%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2026

Drug store¥478.4B
57%
Op. margin 5.7%Industry: Drugstores & Pharmacies
Discount store¥364.1B
43%
Op. margin 5.3%Industry: Supermarkets

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第63期(2025/04/01－2026/03/31)
ID S100YL7Q2026-06-26Open
EDINET (FSA Japan)
有価証券報告書－第62期(2024/04/01－2025/03/31)
ID S100VZPP2025-06-19Open
EDINET (FSA Japan)
有価証券報告書－第61期(2023/04/01－2024/03/31)
ID S100TP0D2024-06-24Open
EDINET (FSA Japan)
有価証券報告書－第60期(2022/04/01－2023/03/31)
ID S100R4PN2023-06-26Open
EDINET (FSA Japan)
有価証券報告書－第59期(令和3年4月1日－令和4年3月31日)
ID S100OH6L2022-06-27Open
EDINET (FSA Japan)
有価証券報告書－第58期(令和2年4月1日－令和3年3月31日)
ID S100LSDT2021-06-28Open

Extracted from XBRL: 50 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open Markdown Share on X Save image